This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Risperidone

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221014

Version

10

Spl Product Data Elements

risperidone risperidone RISPERIDONE RISPERIDONE ASPARTAME CALCIUM STEARATE CROSPOVIDONE (15 MPA.S AT 5%) MANNITOL PEPPERMINT SODIUM LAURYL SULFATE DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER WHITE TO OFF-WHITE FLAVOR FIRMENICH POWDER PEPPERMINT ROUND ZD;22 risperidone risperidone RISPERIDONE RISPERIDONE ASPARTAME CALCIUM STEARATE CROSPOVIDONE (15 MPA.S AT 5%) MANNITOL PEPPERMINT SODIUM LAURYL SULFATE DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER WHITE TO OFF-WHITE FLAVOR FIRMENICH POWDER PEPPERMINT ROUND ZD;21 risperidone risperidone RISPERIDONE RISPERIDONE ASPARTAME CALCIUM STEARATE CROSPOVIDONE (15 MPA.S AT 5%) MANNITOL PEPPERMINT SODIUM LAURYL SULFATE DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER WHITE TO OFF-WHITE FLAVOR FIRMENICH POWDER PEPPERMINT ROUND ZD;20

Application Number

ANDA078516

Brand Name

Risperidone

Generic Name

risperidone

Product Ndc

65841-641

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-640-06 in bottle of 30 tablets Risperidone Orally Disintegrating Tablets, 0.5 mg Rx only 30 tablets NDC 65841-641-06 in bottle of 30 tablets Risperidone Orally Disintegrating Tablets, 1 mg Rx only 30 tablets NDC 65841-642-06 in bottle of 30 tablets Risperidone Orally Disintegrating Tablets, 2 mg Rx only 30 tablets Risperidone Orally Disintegrating Tablets Risperidone Orally Disintegrating Tablets Risperidone Orally Disintegrating Tablets

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.